Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Articles Article Faculty Publications -Articles Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer Subject The topic of the resource breast cancer; doxorubicin; gene-drug co-delivery; HER2 siRNA; RNA interference Description An account of the resource The present study investigated the concurrent delivery of antineoplastic drug, doxorubicin, and HER2 siRNA through a targeted theranostic metallic gold nanoparticle designed using polysaccharide, PSP001. The as-synthesized HsiRNA@PGD NPs were characterized in terms of structural, functional, physicochemical, and biological properties. HsiRNA@PGD NPs exposed adequate hydrodynamic size, considerable ? potential, and excellent drug/siRNA loading and encapsulation efficiency. Meticulous exploration of the biocompatible dual-targeted nanoconjugate exhibited an appealing biocompatibility and pH-sensitive cargo release kinetics, indicating its safety for use in clinics. HsiRNA@PGD NPs deciphered competent cancer cell internalization, enhanced cytotoxicity mediated via the induction of apoptosis, and excellent downregulation of the overexpressing target HER2 gene. Further in vivo explorations in the SKBR3 xenograft breast tumor model revealed the appealing tumor reduction properties, selective accumulation in the tumor site followed by significant suppression of the HER2 gene which contributed to the exclusive abrogation of breast tumor mass by the HsiRNA@PGD NPs. Compared to free drugs or the monotherapy constructs, the dual delivery approach produced a synergistic suppression of breast tumors both in vitro and in vivo. Hence the drawings from these findings implicate that the as-synthesized HsiRNA@PGD NPs could offer a promising platform for chemo-RNAi combinational breast cancer therapy. 2024 American Chemical Society. Creator An entity primarily responsible for making the resource Archana M.G.; Anusree K.S.; Unnikrishnan B.S.; Reshma P.L.; Syama H.P.; Sreekutty J.; Joseph M.M.; Sreelekha T.T. Source A related resource from which the described resource is derived ACS Applied Materials and Interfaces, Vol-16, No. 20, pp. 25710-25726. Publisher An entity responsible for making the resource available American Chemical Society Date A point or period of time associated with an event in the lifecycle of the resource 2024-01-01 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.1021/acsami.4c02532" target="_blank" rel="noreferrer noopener">https://doi.org/10.1021/acsami.4c02532</a> <br /><br /><a href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194112675&amp;doi=10.1021%2Facsami.4c02532&amp;partnerID=40&amp;md5=18b9e63caf062b8456f53e3e79b3cce6" target="_blank" rel="noreferrer noopener">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194112675&amp;doi=10.1021%2facsami.4c02532&amp;partnerID=40&amp;md5=18b9e63caf062b8456f53e3e79b3cce6</a> Rights Information about rights held in and over the resource Restricted Access Relation A related resource ISSN: 19448244; PubMed ID: 38739808 Format The file format, physical medium, or dimensions of the resource Online Language A language of the resource English Type The nature or genre of the resource Article Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Archana M.G., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Anusree K.S., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Unnikrishnan B.S., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India, Centre for Nanotechnology, Indian Institute of Technology (IIT), Uttarakhand, Roorkee, 247667, India; Reshma P.L., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Syama H.P., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Sreekutty J., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Joseph M.M., Chemical Sciences &amp; Technology Division (CSTD), Organic Chemistry Section, CSIR-National Institute for Interdisciplinary Science &amp; Technology (CSIR-NIIST), Kerala, Thiruvananthapuram, 695019, India, Department of Life Sciences, CHRIST University, Banglore, 560029, India; Sreelekha T.T., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India